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ABSTRACT

Migraine is a neurological disease marked by recurrent headache and migraine
attacks. Migraine is one of the most common diseases in the world, and as a result of high
prevalence and symptoms, migraine is also quite disabling. One-third of people who have
migraine experience aura, and these individuals have a greater risk for stroke, psychiatric
comorbidities, and suicide attempts. The present study aimed to evaluate if there was a
difference in headache-related disability between those who have migraine with and
without aura, and any headache or psychiatric factors that may account for observed
difference in disability.
The present study is an observational study of daily diary data from the N1Headache™ App. We compared daily reports of headache-related disability between
those with and without aura, before and after accounting for potential differences in
headache symptoms and psychiatric variables. An omnibus comparison of mean
disability across all attacks yielded a statistically significant difference between groups
(M aura = 1.40 [1.08] vs 1.08 [1.00], p < .001). However, a more conservative analysis of
disability differences using only the first attack found no statistically significant
difference in disability between attacks with and without aura (M = 1.30 [1.08] vs 1.21
[1.01], p = .28). Subsequent ANCOVA confirmed this null result after controlling for
headache and psychiatric covariates.
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INTRODUCTION
Migraine
Defining migraine. Migraine disease is characterized by recurrent episodes of
severe headache and associated symptoms (Miller et al, 2014). According to the
International Classification of Headache Disorders 3 (ICHD-3; Headache Classification
Committee, 2018), the criteria for a migraine diagnosis is a history of at least five attacks
that last 4-72 hours untreated or unsuccessfully treated, with at least two of the following
four symptoms: unilateral location, pulsating quality, moderate or severe pain intensity,
and aggravation by or causing avoidance of routine physical activity. Attacks also must
include at least one of the following: nausea, vomiting, or both photophobia (sensitivity
to light) and phonophobia (sensitivity to sound) (Headache Classification Committee,
2018). Migraine can be “episodic,” with less than 15 headache days per month, or
“chronic,” with at least 15 headache days a month (at least 8 of which are migraine days)
for more than 3 months (Seng et al, 2017).
Pathophysiology. Migraine originates from the brain and its associated tissues.
The major contributing areas that affect migraine are the central nervous system, the
peripheral nervous system, and the trigeminovascular system (Pietrobon & Moskowitz,
2013), although the precise pathophysiology of a migraine attack is not fully understood.
Most recently, the pain-signaling peptide calcitonin gene related peptide (CGRP) has
been strongly linked to migraine. Indeed, experimental studies show that infusion of
CGRP in those with migraine induces an attack that can be reversed when CGRP is
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removed (Pietrobon & Moskowitz, 2013). Moreover, a large and growing class of CGRP
antagonists has shown efficacy in the treatment of migraine (Camporeale et al., 2018;
Dodick et al., 2018). Migraine has a strong genetic component as well, with heritability
assumed to be as high as 50% (Peitrobon & Moskowitz, 2013).
Prevalence. Migraine has an estimated global prevalence of 14.9% (Burch et al,
2015) and is the third most common disease in the world (Steiner et al, 2013). In 2016, it
was estimated that over 1 billion people had migraine (GBD 2016 Headache
Collaborators, 2016). Migraine is three times more common in females than males, and
out of every four women, one will experience migraine at some point in life (Smitherman
et al, 2013). One of the reasons why migraine is more prevalent in women is due to the
influence of hormones. Menarche, puberty, the menstrual cycle, pregnancy, and
menopause can all have an effect on migraine presentation in women, as fluctuations in
ovarian hormones (i.e., estrogen and progesterone) can influence headache patterns
(Pakalnis, 2016). Migraine is most prevalent in early to middle adulthood and is inversely
related to educational attainment and income (Smitherman et al, 2013). Migraine is also
less common in Blacks than Whites (Lipton et al, 2007). As migraine is quite prevalent
globally, it has a large effect on disability.
Disability. Worldwide, migraine is the seventh leading cause of disability and the
leading cause of disability among all neurological disorders (Steiner et al, 2013). The
2016 Global Burden of Disease Study estimated that migraine caused 45.1 million years
lived with disability (YLDs) (GBD 2016 Headache Collaborators, 2016). From the period
of 2009-2010, headache or head pain registered as the fourth leading cause for
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presentation at the Emergency Department (ED; Burch et al, 2015). Due to migrainerelated disability, both individual and societal costs result (Seng et al, 2017).
As of 2016, the annual direct and indirect costs of migraine in the United States
amounted to $36 billion. On an individual level, having migraine results in higher direct
and indirect costs, summing to $8924 per person in 2014 US dollars (USD). Direct costs
include medical expenses such as doctor and hospital visits, as well as medication, and
total to $6575 per person (in 2014 USD). Indirect costs are accounted for by time lost due
to reduced productivity, missed days of work, or other missed activities and total to
$2350 per person (in 2014 USD; (Bonafede, 2018). Over half (53.7%) of people with
migraine report severe impairment or a need for bed rest during attacks (Lipton et al,
2007). Because those with chronic migraine have more migraine days, and are therefore
more heavily burdened by migraine, they experience greater disability than those with
episodic migraine (Bigal, 2003). They also have higher direct and indirect costs
(Bonafede, 2018). For instance, Stokes et al. (2011) found that mean individual 3-month
cost for chronic migraine was $1036 versus $383 for episodic migraine. Increased risk for
comorbid psychiatric disorders further compounds the already high burden of migraine.
Psychiatric comorbidities. Those with migraine tend to have higher rates of
psychiatric comorbidities, such as depression and anxiety disorders, than individuals
without migraine (Smitherman et al, 2013). Overall, the presence of migraine is
associated with at least doubled risk for having a mood or anxiety disorder. For instance,
the risk of panic disorder is three times higher, and the risk of generalized anxiety
disorder five times higher, for individuals with migraine compared to individuals without
migraine (Buse et al, 2013). Those with migraine are also at higher risk for depression

Disability and Migraine Aura 5

(Radat & Swendsen, 2005), such that several studies indicate that about 40% of those
with migraine also meet criteria for depression (Buse et al, 2013). The presence of these
comorbidities is associated with increased levels of disability experienced (Buse et al,
2013). Comorbidities are more common in those with chronic migraine than with
episodic migraine and may function as a factor contributing to progression from episodic
to chronic migraine over time (Buse et al., 2013).
Aura
Definition/Mechanism. Aura is a temporary visual or sensory experience that
may serve as a warning sign that a potential migraine attack is forthcoming. Specifically,
the criteria for migraine with aura involve at least two attacks of fully reversible visual,
sensory, speech, motor, brainstem, or retinal symptoms with two or more of the
following: gradual symptom spread over five or more minutes or multiple symptoms
occur in succession; symptom duration of 5-60 minutes; unilateral presentation; and
accompanied or followed within 1 hour by headache (Headache Classification
Committee, 2018, 2018). Commonly, aura symptoms are visual (99%), but sensory
(31%), speech (18%) and motor (6%) symptoms can also occur (Miller & Matharu 2014).
Migraine aura is believed to be caused by cortical spreading depression. Cortical
spreading depression manifests as a disruption of the cerebral cortex and is characterized
as a depolarization wave that travels the cortex at a rate of 3-5 mm/min (Lauritzen, 1994).
The brain can be more susceptible to aura depending on a variety of factors including
genetics, neural activity, gender, and hormonal status (Kurth et al, 2012.) Studies of those
who have aura revealed a deficient regulatory mechanism of cortical excitability,
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resulting in a reduced ability to avert extreme escalations in cortical excitation (Pietrobon
& Moskowitz, 2013).
Prevalence. One-third of those with migraine experience aura symptoms
(Pietrobon & Moskowitz, 2013). According to an older epidemiological comparison
study, the female to male ratio of migraine with aura is 2:1, and in migraine without aura
it is 7:1 (Rasmussen & Olesen, 1992). Although no age correlation was found, women
were more likely to have migraine without aura than migraine with aura. Among females,
hormonal influences in migraine were more often associated with migraine without aura
than migraine with aura. In those who have migraine with aura, headache attacks tended
to be shorter in duration and less severe than in migraine without aura (Rasmussen &
Olesen, 1992).

Influence of Aura on Headache-Related Disability
A small but growing body of literature suggests that migraine aura is associated
with increased risk for a number of negative consequences. Previous studies have shown
that individuals who have migraine with aura are at greater risk for stroke (Kurth et al,
2012) and more likely to have psychiatric comorbidities than people who have migraine
without aura (Breslau, 1998; Radat & Swendsen, 2005; Wang et al 2007). For instance, a
study by Breslau (1998) compared those with no migraine, migraine without aura, and
migraine with aura on a number of psychiatric comorbidities. Major depression was
present in 9%, 22%, and 32% of the respective groups, while any anxiety disorder was
present in 27%, 51% and 58%. After adjusting for participant sex, compared to those
without migraine, those with migraine with aura were at four-fold greater risk for major
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depression (odds ratio 2.2 for migraine without aura) and three-fold greater risk for any
anxiety disorder (odds ratio 2.3 for those without aura). Additionally, compared to those
that have migraine without aura, people that have migraine with aura are at greater risk
for substance use disorders and suicide attempts (Breslau, 1998). However, studies
specifically assessing relations between aura and headache-related disability are lacking.
Purpose of the Present Study
The primary purpose of the present study was to assess if there is a difference in
headache-related disability between those who have migraine with and without aura. We
hypothesized that aura will be associated with greater headache-related disability as
compared to migraine without aura, as a function of increased comorbid symptoms
among those with aura. Secondarily, the purpose of this study was to look at factors that
may account for any observed difference in disability. We hypothesized that after
controlling for other headache variables (ie, pain intensity, migraine frequency, headache
duration) and daily ratings of stress, sleep and emotional variables, any observed
differences in disability would no longer be present.

METHODS
Design and Setting
The present study is an observational study of daily diary data from the N1Headache™ App (previously named Curelator Headache™), a commercially available
digital health platform for tracking migraine and related variables. This app allows the
user to record headache symptoms and disability every day and allows visualization of
this data over time. During the registration process, participants were asked to consent
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that their data could be used for research and publication purposes via acceptance of
Curelator Inc. Terms and Conditions and Privacy Policy. The Biomedical Research
Alliance of New York (BRANY) IRB granted a waiver of informed consent and
approved use of participant data for analysis and publication. Data collection took place
from October 2014-May 2018. At this time, N1-Headache™ was available only on iOS
via the Apple App Store and only offered in English. User information and privacy was
protected by the authentication, encryption, security awareness programs, and code
reviews.
Participants
Participants were recruited indirectly by voluntarily downloading and signing up
for the N1-Headache App and agreeing to share their de-identified data with Curelator.
The majority of participants were from English speaking countries. The inclusion criteria
for the present study were adults with episodic migraine of 5 -14 days per month who
tracked for at least 90 days within 120 calendar days (75% compliance or greater,
consistent with a prior study using this dataset; Vives-Mestres et al., 2020).
Measures
MIDAS. The Migraine Disability Assessment (MIDAS; Lipton et al., 2001) scale
is a widely-used measure of migraine interference that accounts for days lost (or where
productivity was reduced) from paid work or school, household work, and other activities
as a function of headache. The MIDAS consists of 5 questions that inquire about number
of days where functioning was lost or reduced due to headache over the last 90 days. In a
previous study, those with episodic migraine were found to have a MIDAS score of 19.3
versus those with chronic migraine, who had a MIDAS score of 34.9 (Bigal et al, 2003).
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For the present study, the MIDAS was administered each day a headache was reported
and modified such that it queried functional impairment specific to that particular day.
For each of the 3 domains of functioning (paid work/school, household work, other
activities) that migraine either prevented or reduced productivity by half or more, a score
of 1 was assigned. Scores on the daily MIDAS used in this study thus range from 0 to 3,
with 3 being indicative of greatest functional impairment.
Headache and Psychiatric Symptoms. The N1-Headache app classifies each
day of tracking as a “migraine day” or a “headache day” based on ICHD-3 criteria,
according to recorded symptoms. Headache duration is reported in hours and peak
severity on a 1-3 scale (1 = mild, 2 = moderate, 3 = severe). Classification of a migraine
day is based on symptoms meeting the ICHD-3 criteria for a migraine attack in the
migraine diagnostic criteria. Classification of a headache day occurs when the user has an
attack that does not meet all the criteria for a migraine attack according to the above
criteria. During migraine attack tracking, the user was asked “Did you experience visual
or other sensory disturbances (aura)?” In addition to tracking headache symptoms,
participants also record whether they took medication, 0-10 ratings for a variety of mood
states (anxiety, irritability, happiness, sadness, angriness, boredom, relaxedness), sleep
duration in hours, 0-10 ratings of sleep quality, whether they felt refreshed after sleep,
menstruation status, and a number of other symptoms (e.g., yawning, neck pain, hunger,
skin sensitivity).
Statistical Analyses
Demographics were calculated using frequency counts and means with standard
deviations. Independent samples t-test was used to compare daily disability between
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migraine attacks with and without aura. ANCOVA was used to compare groups on
disability after controlling for covariates.
RESULTS
Demographics
Of the 604 participants, 533 (88.2%) were female, 70 were male (11.6%) and 1
person identified as “other.” This disproportionate gender distribution was expected, as
migraine is much more common in women than men (Smitherman et al, 2013). The age
range of participants varied from 18 to 76, with a mean age at app registration of 42.80
(SD = 12.4). 260 participants were from the United States (43.0%), 204 from Great
Britain (33.8%), 30 from Canada (5.0%), 18 from Austria (3.0%), 15 from Australia
(2.5%), 11 from the Netherlands (1.8%), and the remainder from other countries (10.9%).
Headache Characteristics
Of the 604 participants, 542 (89.7%) reported a prior diagnosis of migraine at the
time of registration. Roughly half of the participants (52.1%) reported how many years
they had been living with migraine. The mean number of years lived with migraine was
21.2 (SD = 12.9), with a range of 0-50 years. Mean number of monthly migraine days,
calculated as the average number of migraine days each month over the first 90 days of
tracking, was 6.9 (3.3) days per month. The mean number of headache days per month
was 10.0 (4.0).
A total of 54,360 days were tracked by the participants. Days were categorized
into one of four phases as a function of onset and reported symptoms: prodrome phase (2
days prior to attack), migraine phase (symptoms of migraine attack present), postdrome
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(2 days after migraine attack symptoms end), and interictal days (days without migraine
or associated symptoms).
Of the 54,360 days, 8,099 (14.9%) were the first day of a migraine attack, on which aura
would be present or absent per ICHD-3, and were analyzed for the present study.
Group Differences in Disability
Using an independent samples t-test, we compared mean disability between firstday attacks with and without aura. Of the 8,099 days, 1429 included aura (17.6%). There
was a statistically significant difference between groups, such that mean disability in
attacks with aura was 1.40 (1.08) and in attacks without aura was 1.08 (1.00), p < .001
(95% confidence interval of the difference = 0.26, 0.37).
As these were not fully independent observations, because they included multiple
attacks from each participant, we re-analyzed disability differences using only the first
attack (with aura for those who experienced aura on at least one attack, and without aura
for those who never experienced aura). Of the 591 first attacks where disability data was
reported (13 attacks did not have disability data), 259 included aura (43.8% first attacks).
There was no statistically significant difference in disability between first attacks with
and without aura (mean disability = 1.30 [1.08] vs 1.21 [1.01], p = .28).
Disability After Controlling for Covariates
To identify potential confounding variables prior to the covariate analysis, we
analyzed potential age and gender differences between individuals who experienced
attacks with and without aura. On average, individuals without aura were approximately
3 years older than those with aura (44.0 [12.6] vs 41.2 [12.0], p = .006). Chi-squared
analysis for gender did not reveal a significant gender difference between group (87.7%
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female without aura vs 89.0% female with aura, p = .43). Age was thus used in
subsequent covariate analyses.
To assess MIDAS differences as a function of aura after considering age and both
headache and psychiatric covariates, ANCOVA was used for the first attack data.
Headache covariates were peak intensity of the attack, duration of the attack, and
monthly migraine frequency. Psychiatric covariates were sleep duration (in hours) and 010 ratings of stress, anxiety and sadness specific to that day. The results of the ANCOVA
showed no significant difference in disability between first attacks with and without aura
after considering the aforementioned covariates, F (9, 548) = 1.463, p = .227. The
estimated marginal means in disability was 1.28 for attacks with aura and 1.18 for attacks
without aura.

DISCUSSION
The present study endeavored to assess disability differences in migraine attacks
with and without aura. We hypothesized that disability would be higher in migraine
attacks with aura but that this difference would no longer be present after controlling for
headache and psychiatric covariates. Contrary to our predictions, there was not a
statistically significant difference in disability in migraine attacks with and without aura.
Although evaluating all migraine attacks across participants yielded the predicted
difference in disability, a subsequent analysis investigating only the first attack (with aura
if the individual experienced aura, without aura if the individual did not) did not replicate
this result. The latter analysis was considered a more robust examination of the
hypothesis because the former did not use independent observations.
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The reason for hypothesizing that migraine attacks with aura would have a higher
disability rating than attacks without aura lies in previously found associations with aura
that we thought might contribute to disability. These include higher stroke risk (Kurth et
al, 2012), higher psychiatric comorbidity risk (Breslau, 1998; Radat & Swendsen, 2005;
Wang et al 2007), and a higher suicide risk (Breslau, 1998). However, controlling for an
observed age difference and both headache and psychiatric symptoms did not alter the
disability results significantly. One possible explanation could be because migraine
attacks including aura have been shown to be shorter in duration and less severe that
attacks without aura (Rasmussen & Olesen, 1992). Perhaps this is because aura can serve
as a warning sign of an impending migraine attack, giving individuals with aura a unique
opportunity to treat their attacks earlier (compared to those without aura). The earlier a
migraine attack is treated, the more likely the treatment is to be effective and likelihood
of need for retreatment reduced (Cady et al, 2000). This may have the effect of lowering
the potential disability individuals might otherwise experience and thus suppress
disability associated with psychiatric symptoms.
These results are also of particular interest in relation to the direct and indirect
costs of migraine, which amounted to $36 billion in the United States in 2016 (Bonafede,
2018). Had it been found that migraine with aura was, on average, more disabling, this
could have implications for clinical management of migraine with aura, such that more
aggressive treatments, or ones that explicitly target disability, might be indicated. Instead,
the null results further support current treatment recommendations, which are largely
similar for both migraine with and without aura (with the exception of avoiding
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medications linked to stroke among those with aura (Edlow & Bartz, 2010; Silberstein et
al, 2021).
The main implication of this study is to show that despite there being
symptomatic and pathophysiological differences between migraine with and without
aura, they do not appear to differ in disability. Despite their differential risk for
psychiatric comorbidities (Breslau, 1998; Radat & Swendsen, 2005; Wang et al 2007),
these comorbid symptoms do not appear to differentially influence disability. Future
research should aim to explore other differences that may exist between migraine with
and without aura so that these two diseases can be better understood, followed by
enacting the development of better targeted therapies for each type of migraine.
The strengths of this study were an extremely large sample size that was relatively
diverse since there were users in lots of different countries. The data that was analyzed
was also collected daily, which helps eliminate factors such as recall bias. The limitations
of the study were that the data were self-reported, and thus individual interpretations of
daily logging questions could vary. The app was also only available in the English
language and only available through IOS. Future research could be exemplified by using
multiple device types and offering the N1-Headache app in other languages. Another
limitation was that psychiatric comorbidities were not formally diagnosed but instead
evaluated through daily ratings of emotional states. This research could be expanded
using a more sophisticated statistical analysis of all reported migraine attacks while
accounting for dependent observations over time.
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